Skip to content
MarketScale
‹ Back to Industries

Sciences

To Create a Private Market Do Governments Need To Kickstart Space Programs?

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA. As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management. “I’m really blessed with the leadership…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · And Diversity.And Strategy at NasaAssociate Administrator for TechnologyBhavya Lal
Share

Key takeaways

01

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA.

02

As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management.

03

“I’m really blessed with the leadership…

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA.

As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management. “I’m really blessed with the leadership at NASA,” she said of her role.

Lal grew up in a STEM family; her father was an electrical engineer and her mother studied math. “The idea that one could be gifted was never even brought up. You did well in school because you worked hard, not because you were smart or had some advantage,” Lal said of her upbringing. “I’ve found the idea that hard work can overcome any disadvantages to be my superpower.”

Daily, Lal has 10 to 15 meetings, which makes for long hours. She works closely with the National Space Council, the Office of Science and Technology Policy, and the Federal Aviation Administration. She has found some of the hardest things in society are not technical but are policy-based and must be examined wholistically with a long-term view.

Governments and individuals or businesses are the space industry customers. However, not many individuals and businesses cannot afford services, so Lal believes the government should kickstart certain programs and then private customers will emerge. “Let’s not have this mad dash to discovering a private market that may not already exist. Let’s work to build it,” she said.

In terms of diversity, Lal emphasized the importance of the fields individuals come from. “There’s a myriad of examples of how disruptive thinking comes from the outside,” she stated. “Our innovations will come from diverse thoughts, not trying to repeat what we’ve done before.”

More in This Series

About the author

CB
Chris Blackerby

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby